Corbus Pharmaceuticals’ (CRBP) “Buy” Rating Reaffirmed at Noble Financial

Noble Financial restated their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP) in a report released on Friday morning.

Several other research analysts have also issued reports on CRBP. BidaskClub upgraded Corbus Pharmaceuticals from a sell rating to a hold rating in a research note on Friday. Cantor Fitzgerald reiterated a buy rating and set a $24.00 price objective on shares of Corbus Pharmaceuticals in a research note on Wednesday, September 20th. Finally, ValuEngine lowered Corbus Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Corbus Pharmaceuticals has a consensus rating of Hold and an average price target of $25.00.

Corbus Pharmaceuticals (NASDAQ:CRBP) opened at $7.10 on Friday. Corbus Pharmaceuticals has a 12 month low of $5.30 and a 12 month high of $10.50. The stock has a market capitalization of $403.32, a price-to-earnings ratio of -11.45 and a beta of 175.11.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. The firm had revenue of $0.80 million during the quarter. equities research analysts expect that Corbus Pharmaceuticals will post -0.6 EPS for the current fiscal year.

In other Corbus Pharmaceuticals news, Director David P. Hochman bought 5,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were bought at an average price of $6.90 per share, for a total transaction of $34,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David P. Hochman bought 10,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were acquired at an average price of $7.08 per share, for a total transaction of $70,800.00. Following the acquisition, the director now directly owns 459,500 shares of the company’s stock, valued at approximately $3,253,260. The disclosure for this purchase can be found here. Insiders have bought 25,336 shares of company stock worth $175,632 in the last 90 days. Company insiders own 11.90% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Artal Group S.A. bought a new stake in shares of Corbus Pharmaceuticals during the second quarter worth $1,575,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Corbus Pharmaceuticals during the second quarter worth $469,000. Vanguard Group Inc. boosted its holdings in Corbus Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,255,429 shares of the biopharmaceutical company’s stock valued at $10,357,000 after acquiring an additional 71,419 shares during the last quarter. California State Teachers Retirement System bought a new position in Corbus Pharmaceuticals in the second quarter valued at about $495,000. Finally, Rhumbline Advisers bought a new position in Corbus Pharmaceuticals in the second quarter valued at about $283,000. Institutional investors own 27.84% of the company’s stock.

WARNING: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.com-unik.info/2018/01/02/corbus-pharmaceuticals-crbp-buy-rating-reaffirmed-at-noble-financial.html.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

What are top analysts saying about Corbus Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corbus Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit